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Abstract 
Non-invasive evaluation of large artery function and structure may improve cardiovascular 
risk stratification. Specific treatments in renal failure can affect arterial function/structure. 
For example, in peritoneal dialysis, a dialysis fluid exchange causes acute central 
hemodynamic effects due to the instilled volume, and in hemodialyzed patients, anemia has 
a flow-independent negative impact on endothelial function that can be corrected by 
erythopoietin administration. 
 Arterial calcification is a common feature in renal failure. In a multicentre European 
study of 1084 dialysis patients abdominal aortic calcification (AAC) was scored from a plain 
lateral abdominal radiograph. AAC increased significantly from L1 to L4 and was related to 
carotid-femoral pulse wave velocity (PWV), independent of age, blood pressure and 
diabetes. Nevertheless, AAC scores and PWV provided complementary predictive 
information for cardiovascular events and mortality at 2 years follow-up. Non-invasive 
assessment of central hemodynamic parameters and endothelial function can be useful to 
unravel pathophysiologic mechanisms in heterogeneous populations such as dialysis 
patients. Semi-quantitative AAC scoring and assessment of PWV are inexpensive, fast and 
reliable methods that can be implemented in routine daily clinical practice to improve 
cardiovascular risk stratification in renal patients. 
 Nutritional 25-OH Vitamin D3 (25(OH)D3) deficiency may be a link between bone and 
vascular disease in uremia. In a study of 52 hemodialysis patients, low 25(OH)D3 levels were 
independently related to increased PWV and reduced brachial artery distensibility, and 
therefore, among the many factors involved in arterial stiffness and vascular calcification, 
nutritional Vitamin D deficiency may be the cheapest and safest to correct. 
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Main Text 
Introduction 
Cardiovascular disease (CVD) remains a major cause of morbidity and mortality in patients 
with chronic kidney disease (CKD), either treated by hemodialysis, peritoneal dialysis or after 
renal transplantation, as well as in earlier stages of CKD not yet requiring renal replacement 
therapy. Several functional and structural arterial alterations can be detected before the 
appearance of clinical manifestations, including endothelial dysfunction, changes in arterial 
geometry and biomaterial properties of the vascular wall, increased reflective properties of 
the vascular system, and vascular calcification. Although highly prevalent among patients 
with CKD, these abnormalities are not specific and also occur in other populations at high 
risk for incident CVD and with ageing. This has led to the concept of renal disease as a model 
of accelerated vascular ageing where vascular changes can already be observed at young 
age. The clustering of traditional risk factors in patients with CKD only partially explains the 
high incidence of CVD, and after multivariate adjustment, kidney function expressed as 
estimated glomerular filtration rate, remains an independent predictor of outcome [1]. 
Therefore research has focused on factors specific to the uremic condition leading to the 
identification of an increasing number of uremic retention solutes with direct vasculotoxic 
effects [2]. The complexity of the different biochemical pathways involved, superimposed on 
the heterogeneous nature of the CKD population (underlying kidney disease, rapid changes 
in dialysis practice and post-transplant care, etc.), has stimulated the interest in markers of 
subclinical vascular damage. Such markers should represent at least intermediate endpoints 
of clinical outcome and ideally be surrogate endpoints with a proven relationship between 
improvement of the parameter and a reduction in events. Moreover, techniques for their 
assessment should be accurate, reproducible and non-invasive. In the renal population, 
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several established surrogate endpoints such as left ventricular hypertrophy or albuminuria 
are often difficult to interpret, non-specific, or even unavailable, depending on the 
underlying kidney disease, residual kidney function and/or dialysis modality. Therefore, 
other noninvasive methods have been used for assessing acute hemodynamic changes as 
well as long term functional and structural alterations of large arteries, in different 
subpopulations of CKD. 
 
Acute hemodynamic effects of dialysis 
Acute hemodynamic changes, mostly episodes of hypotension, during hemodialysis (HD) are 
well known to be related to worse outcome. Most physicians presume that an acute 
peritoneal dialysis (PD) dwell does not produce acute hemodynamic changes, which might 
explain why the topic has been investigated only to a limited extent. The few studies 
evaluating changes in hemodynamic parameters indicate however that some mild changes 
in blood pressure (BP) and vascular tone do occur during an acute dwell [3,4]. Such 
repetitive undulations in hemodynamic status can potentially be harmful, as they might 
increase cardiac workload, induce oxidative stress and can negatively impact residual renal 
function [5]. The intraperitoneal (IP) instillation of dialysate causes an abrupt increase in the 
IP pressure. This could enhance venous retour to the right ventricle and this way improve 
cardiac output, or reduce venous return by compressing the vena cava inferior and decrease 
cardiac output.  
 Ivarsen et al. [6] analyzed the evolution of cardiac output using foreign gas 
rebreathing in 15 PD patients, following the instillation of 2 to 3 liters of PD fluid, and this in 
the supine and upright position. In the supine position, no effect of a 2 liter infusion was 
observed. In the upright position, a decrease in cardiac output, and an increase in peripheral 
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systemic resistance was observed, resulting in an absence of a net change in BP. Remarkably, 
the results were not different when either using a 2- or a 3-liter fill, and no change in heart 
rate was observed. Boon et al. [3], using fingertip continuous pressure monitoring, found an 
increase in BP and peripheral resistance after instillation of 2 liters of glucose based 
peritoneal dialysate, an effect they attributed either to compression of the mesenteric 
resistance vessels or to the low temperature. Unfortunately, in these studies, hypertonic 
glucose solutions were used, so an eventual impact of hyperosmolarity and/or glucose 
cannot be excluded. By instillation of a non-glucose containing solution (icodextrin; Baxter 
Healthcare, Ireland), at neutral pH and warmed to 37.0°C, we demonstrated that the 
increase in IP pressure (2.3 cm H2O) closely paralleled a change in hemodynamic parameters 
[7], pointing to the impact of IP volume per se. The effect of IP volume occurs mostly in the 
beginning of the filling procedure, with a rise in carotid systolic BP and augmentation 
pressure of 4.7 mmHg and 3.1 mmHg, after infusion of the starting volume. Augmentation 
index (AIx) increased by 5.7% and heart rate decreased by 2.6/minute, while carotid-femoral 
pulse wave velocity (PWV) remained unchanged. No additional hemodynamic changes 
except for a rise in diastolic BP with increasing volume were observed after subsequent 
addition or removal of volumes. These effects persisted until complete drainage of the 
abdomen and may be due to an enhanced preload, resulting from IP venous compression, 
and/or increased wave reflection. Of note, changes in brachial systolic and diastolic BP were 
not significant, illustrating the importance of studying central hemodynamic parameters 
based on accurately calibrated tonometric waves [8]. A rise of 4.7 mmHg in central systolic 
pressure may appear to be small, but is similar to the difference in the two treatment arms 
of the CAFÉ study (4.3 mmHg), considered to be responsible for the different clinical 
outcomes [9]. The observed hemodynamic effects are in line with a study by Selby et al. [10] 
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where in automated peritoneal dialysis patients, BP decreased during the drain, and 
increased during the instillation of dialysate (unfortunately all glucose based). The decrease 
in BP was correlated with a decrease in peripheral resistance and an incomplete 
compensatory rise in cardiac output.  
 Using hypertonic 3.86% glucose, Selby et al. [4] found an increase in BP and cardiac 
output during the dwell, irrespective of the biocompatibility of the solution used. Our group 
[11], in contrast, was not able to confirm these results. Despite a significant rise in serum 
glucose and insulin levels over time, more pronounced during the high glucose dwell, there 
was no demonstrable effect on central systolic or diastolic BP in this study. One of the 
reasons for the discrepancies between these two studies may relate to the different 
methodology used to measure hemodynamic parameters. We chose to set up this study 
using the SphygmoCor system (AtCor Medical, Sydney, Australia) and to measure at the level 
of the carotid artery, as this approach yields more accurate estimates of central 
hemodynamic measurements [12]. Finger arterial pressure tracing with Modelflow pulse 
wave analysis (Finometer; Finapres Medical Systems, Arnhem, The Netherlands) as used in 
studies by Selby [4,10,13], in contrast, has only been validated for assessing brachial artery 
pressure [14] and has been shown to be insufficiently accurate in specific conditions, such as 
pregnancy [15]. 
 
Long term effects of anemia and Vitamin D deficiency 
Physiologic laminar fluid shear stress (SS) is responsible for endothelial cell survival and 
quiescence and their secretion of substances that favour anticoagulation, inhibit 
inflammation, induce vasodilation, and exert atheroprotective effects in vivo [16,17]. In 
patients with end-stage renal disease, outward remodeling, arterial stiffness, and impaired 
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endothelial function are observed. Flow mediated dilation is often used as a reference 
method for studying biomarkers of endothelial dysfunction or evaluating the effect of 
interventions. In clinical studies, non-pharmacalogical interventions used to increase flow 
are distal limb ischemia or skin heating. Although the resulting vasodilatatory reponse is 
termed flow-mediated dilation (FMD), the actual physical stimulus acting upon the 
endothelial surface is the increase in shear stress (SS), not the increase in flow itself. 
Endothelial dysfunction and arterial stiffness appear to be linked, although the exact 
mechanisms remain unclear. High SS induces acute changes of the conduit artery function 
(FMD) [18] and arterial remodelling with modified arterial wall properties [19]. The 
prognostic importance of an impaired FMD was demonstrated in a study of 78 HD patients, 
showing that lower postischemic forearm reactive hyperemia was predictive of all-cause 
mortality, independent of aortic PWV [20]. 
 With the advancement in electronics and computer technology, it became possible to 
directly measure the shear rate (SR) close to the arterial wall (endothelial surface), which 
enables, in combination with the measurement of whole blood viscosity (WBV), to quantify 
SS as the product of SR x WBV. With a high-resolution echo-tracking device (Wall-track 
System; Pie Medical, Maastricht, The Netherlands), changes in flow velocity profiles and 
diameter were studied in 44 HD patients, following progressive hand warming-induced 
hyperemia. The use of skin heating as flow stimulus allows to quantify the vasodilation in 
response to different known levels of endothelial stimulation. Using this approach, the flow-
independent negative impact of anemia-associated low WBV on levels of SS could be 
demonstrated [21]. The concurrent improvement in SS and FMD following anemia correction 
by erythropoietin administration supports a causal role of anemia in endothelial dysfunction, 
consistent with the known adverse effect of low SS on endothelial function [22]. Because SS 
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is the real physical stimulus acting upon the endothelium, future studies should take into 
account the independent effects of both flow and blood viscosity. Likewise, the results of 
interventions such as erythropoietin treatment looking only to hemoglobin/hematocrit (as a 
proxy for WBV) may be difficult to interpret without any information on arterial wall and 
blood flow characteristics. A benefit can only be expected when there is at least some 
degree of endothelial function left and when the artery is capable of dilating at all 
(preserved endothelial independent vasodilation), which may not be the case in the majority 
of patients included in previous randomized trials. This may be one explanation for the 
seemingly contradictory results of our and previous studies [23-25] compared to those of 
intervention studies showing no benefit or even a worse outcome at higher levels of target 
hemoglobin [26-28]. Moreover, in our study, care was taken not to “overcorrect” (i.e. 
normalize) the anemia to levels as achieved in the higher hemoglobin/hematocrit arms of 
these randomized trials [26-28]. 
 The role of 25(OH) Vitamin D and 1-25(OH)2 Vitamin D in the pathophysiology of 
Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD), including CVD 
complications, continues to be an area of intensive research. Most large epidemiological 
studies and interventional trials focused on either PTH, calcium and phosphorus levels, or 
the use of active Vitamin D analogues, producing rather inconsistent or even conflicting 
results. Nutritional 25(OH)Vitamin D deficiency is highly prevalent in renal populations and 
supplementation is safe and inexpensive. In a cross-sectional study of 52 HD patients, we 
observed a consistent and independent relationship between a deficiency in both Vitamin D 
forms and increased arterial stiffness, reduced distensibility as well as endothelial 
dysfunction, pointing to a potential new mechanism involved in the functional and structural 
alterations of large arteries in dialysis patients [29]. Since calcification status and 
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abnormalities in serum levels of calcium, phosphorus or PTH, were not independently 
related to Vitamine D status, studies addressing CVD risk in relation to CKD-MBD should 
measure both vascular calcification as well as stiffness. Future studies should further 
establish the causal role of nutritional and hormonal vitamine D deficiency in inducing 
stiffness, and the pathophysiological pathways involved. This information, in turn, could also 
help to better define the indications for treatment with active Vitamine D or their analogues. 
 
Calcification, stiffness and wave reflections in epidemiologic studies 
The Calcification Outcome in Renal Disease (CORD) study is currently the largest study in 
dialysis patients to assess at the same time parameters of arterial stiffness, wave reflection 
and vascular calcification, and their predictive value for patient outcome. In this 
epidemiologic study, abdominal aortic calcification, carotid-femoral PWV, and central AIx 
were measured in 1084 dialysis (both HD and PD) patients, recruited from 47 European 
dialysis centers across 6 European countries. Calcification was assessed by semiquantitative 
scoring of a plain lateral lumbar radiograph (AAC scores) according to a validated method 
[30]. In previous studies, methods used to quantify the extent of calcification were more 
expensive, like electron beam computed-tomography [31], or more time-consuming with the 
use of both utrasonographic and radiographic imaging at different anatomical sites [32]. 
Although computed-tomography based methods remain the golden standard for 
quantification, a plain lateral lumbar X-ray is far less expensive and readily available. 
Moreover, a recent study demonstrated that abdominal X-ray scoring had a very good 
discriminatory value compared with coronary artery calcification (CAC) scores, with an area 
under curve of the receiver-operating characteristic above 0.70 at each CAC threshold [33]. 
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 The cross-sectional evaluation of the abdominal aortic calcification clearly showed 
the magnitude of the problem nephrologists are facing [34]. Over 80% of patients had visible 
calcifications (AAC score ≥ 1), and in more than half of the population all 4 lumbal levels 
were affected. The number of patients affected and the severity of calcification increased 
progressively from L1 to L4, indicating that calcification developed in a distal to proximal 
direction, consistent with findings of large post-mortem studies performed in the sixties 
[35].  
 As in recent analyses of the population-based Rotterdam study [36] and the Anglo-
Cardiff Collaboration Trial [37], as well as in a study of 131 HD patients [38], PWV was 
independently related to abdominal aorta calcification [39], supporting the prevailing 
hypothesis that calcification in dialysis patients is predominantly medial wall calcification 
which contributes to stiffness. The progressive increase in PWV with increasing quintiles of 
AAC scores is illustrated in Figure 1. In contrast, AIx only weakly correlated with AAC and was 
mainly related to heart rate and anthropometric factors. Although calcification and 
increased PWV clearly clustered in older patients with established CVD, still 1/3 of 
apparently low risk patients had aortic calcifications and/or abnormal values of PWV or AIx. 
Since these patients are generally considered candidates for renal transplantation, 
assessment of abdominal aortic calcification, PWV and AIx would be of particular value in 
this population. Detection of abdominal calcification in transplant candidates could also 
prompt further imaging of the adjacent iliac arteries and result in an early detection of 
potential lesions that may be relevant for the surgical procedure. The cross-sectional data of 
the CORD study also confirm the notion that CKD is a metabolic disorder characterised by 
accelerated vascular ageing. Indeed, CORD patients aged 25-35 years had a mean AIx and 
PWV comparable with values observed in the fifth decade in healthy persons (figure 2). 
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 In the CORD study, after a median follow-up of 2 years, 234 deaths and 91 nonfatal 
cardiovascular events were recorded, corresponding to an incidence rate of 15% per year. 
AAC and PWV each individually were strong predictors of outcome, confirming earlier 
studies in HD patients. The combined information of AAC and PWV, however, further 
improved risk prediction, despite the fact that abdominal aortic calcification and PWV are 
strongly related [40]. This provided evidence that both should be measured when assessing 
CVD risk in the dialysis patient. 
 Additional analyses of the CORD data are in progress, and some preliminary results 
have been reported in abstract form. It was shown that the change in PWV over the two 
year observation period was related to outcome, independently from the baseline value, 
which further supports the role of PWV as a surrogate endpoint and its potential value for 
the follow-up of patients [Verbeke F et al., J Am Soc Nephrol. 2007; 18: 69A (FC006)]. In a 
similar analysis of the change in AAC scores over time, it was found that calcification 
progressed by 2 AAC-score points per year [Honkanen E et al., J Am Soc Nephrol. 2008; 19: 
718A (PO2693)] as compared to 0.3 points in the historical Framingham cohort [30]. Finally, 
from an analysis of different parameters of wave reflection, central augmentation pressure 
was superior in predicting outcome compared to peripheral and central augmentation index 
[Verbeke F et al. J Am Soc Nephrol. 2008; 19: 11A (FC047)]. 
 
Conclusions and future perspectives 
With the use of applanation tonometry, it was demonstrated that an acute instillation of PD 
fluid increases central but not peripheral BP. The effects are attributed to the increase in IP 
pressure during the filling procedure and persist for several hours. Although the underlying 
mechanisms remain incompletely understood, the concommitant rise in AIx suggests that 
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enhanced wave reflection may play a role. The effect of hyperglycemia is debated, but the 
use of nonhypertonic glucose-based solutions seem to be without or of very limited 
hemodynamic effect. Therefore, from the available PD regimens, those with high volume, 
fast cycling hypertonic exchanges should be avoided. 
 The evaluation of endothelial function by FMD is time-consuming, requires a high 
level of technical expertise as well as an expensive ultrasound equipment, but provides the 
most complete and detailed information. It allowed to demonstrate that correction of 
anemia by erythropoietin administration improves FMD by increasing SS, an effect that is 
attributable, at least in part, to an increased WBV. This information is clinically relevant 
because it had been shown previously that impaired endothelial function is predictive of 
mortality. Another advantage is that endothelial function can be affected on the short term 
whereas changes in structural properties of the arterial wall, such as stiffness and 
calcification, may only occur over long periods of time.  
 CORD is the first study that implemented simple and inexpensive yet reliable and 
validated methodologies on a large scale and in daily clinical conditions. CORD has paved the 
way for the use of AAC-scoring and applanation tonometry in daily clinical nephrology 
practice and in future studies. Meanwhile, PWV has been adopted as a marker of target 
organ damage in the latest 2007 ESH/ESC hypertension guidelines, and the accumulating 
evidence supporting the independent prognostic value of vascular calcification urges to 
consider also this parameter for CVD risk assessment in renal populations. Following the 
logic of disease prevention, the next step will be to look for therapeutic strategies that may 
affect abdominal aortic calcification and PWV favourably and hopefully will also improve 
outcome. Obviously, the maximal benefit is to be expected from screening and intervention 
at earlier stages of kidney disease. Therefore, efforts should focused on patients with CKD 
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stage 3 to 5 not yet on dialysis, or even earlier like in patients with heavy proteinuria and at 
high risk for rapid loss of kidney function, or in persons that are considered for living kidney 
donation.  
 The use of these measures will be valuable in the design and interpretation of future 
randomized trials and help us to understand the negative or conflicting results of previous 
studies. It should be verified whether treatment with calcium-containing versus calcium-free 
phosphate binders in patients with different levels of abdominal aortic calcification and PWV 
at the start affects these parameters and subsequent outcomes in the same way. The 
consistent cross-sectional relationship between nutritional Vitamin D deficiency and indices 
of arterial stiffness and endothelial dysfunction, points to one of the therapeutic targets to 
be prioritized in future studies and may be part of a pathophysiological link between bone 
and mineral disorders, and CVD in dialysis patients. Such interventional studies will also help 
to define therapeutic thresholds as well as limits of abdominal aortic calcification and PWV 
values beyond which an intervention is unlikely to affect outcome.  
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Figure Legends 
Figure 1  
Relationship between AAC scores (quintiles) and PWV in the CORD study. 
The lowest quintile of AAC scores corresponds to the subgroup of patients without any 
visible calcification (AAC = 0).  
 
Figure 2 
Mean AIx (grey bars) and PWV (black bars) according to age in CORD patients compared with 
the general population (adapted from McEniery et al. J Am Coll Cardiol 2005;46:1753-60; 
dashed and solid lines represent average AIx and PWV, respectively). Values in CORD 
patients at age 25-35 years are comparable with those of the general population at age 45-
55 years (dotted lines). 
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